References
- Kyle R. A. Plasma cell proliferative disorders. Hematology: Basic principles and practice, Hoffman, et al. Churchill Livingstone, New York, New York 1995; 1354–1375
- Kyle R. A. Diagnostic criteria of multiple myeloma. Hematology/Oncology Clinics of North America 1992; 6: 347–358
- Duggan D. B., Schattner A. Unusual manifestations of monoclonal gammopathies. Auto‐immune and idiopathic syndromes. American Journal of Medicine 1986; 81: 864–870
- Greipp P. R. Advances in the diagnosis and management of myeloma. Seminars of Hematology 1992; 29(suppl 2)24–45
- Ong F., Hermans J., Noordijk E. M., Kluin‐Nelemans J. C. Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population‐based registry of paraproteinemia and multiple myeloma. Annals of Hematology 1995; 70: 19–24
- Lymphoma Tumour Group. Plasma cell disorders. Cancer treatment policies, 4–6. British Columbia Cancer Agency, British ColumbiaCanada 1992
- Durie B. G. M., Salmon S. E. A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854
- Durie B. G. M. Staging and kinetics of Multiple Myeloma. Seminars of Oncology 1986; 13: 300–309
- Bladé J., Lust J. A., Kyle R. A. Immunoglobulin D multiple myeloma: Presenting features, response to therapy, and survival in a series of 53 cases. Journal of Clinical Oncology 1994; 12: 2398–2404
- Kyle R. A., Greipp P. R. Plasma cell dyscrasias: current status. Critical Reviews of Oncology and Hematology 1988; 8: 93–152
- Cavo M., Galieni P., Gobbi M., Baldrati L., Leardini L., Baccarani M., Tura S. Non‐secretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematologica 1985; 74: 27–30